These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

637 related items for PubMed ID: 18638016

  • 21. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
    Hezzell MJ, Block CL, Laughlin DS, Oyama MA.
    J Vet Intern Med; 2018 Sep; 32(5):1509-1516. PubMed ID: 30216549
    [Abstract] [Full Text] [Related]

  • 22. Increased NT-proANP predicts risk of congestive heart failure in Cavalier King Charles spaniels with mitral regurgitation caused by myxomatous valve disease.
    Eriksson AS, Häggström J, Pedersen HD, Hansson K, Järvinen AK, Haukka J, Kvart C.
    J Vet Cardiol; 2014 Sep; 16(3):141-54. PubMed ID: 25130405
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study).
    Summerfield NJ, Boswood A, O'Grady MR, Gordon SG, Dukes-McEwan J, Oyama MA, Smith S, Patteson M, French AT, Culshaw GJ, Braz-Ruivo L, Estrada A, O'Sullivan ML, Loureiro J, Willis R, Watson P.
    J Vet Intern Med; 2012 Sep; 26(6):1337-49. PubMed ID: 23078651
    [Abstract] [Full Text] [Related]

  • 24. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.
    Atkinson KJ, Fine DM, Thombs LA, Gorelick JJ, Durham HE.
    J Vet Intern Med; 2009 Sep; 23(6):1190-6. PubMed ID: 19780931
    [Abstract] [Full Text] [Related]

  • 25. Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease.
    Yata M, Kooistra HS, Beijerink NJ.
    J Vet Intern Med; 2019 Mar; 33(2):462-470. PubMed ID: 30703246
    [Abstract] [Full Text] [Related]

  • 26. Pimobendan in heart failure therapy--a silver bullet?
    Gordon SG, Miller MW, Saunders AB.
    J Am Anim Hosp Assoc; 2006 Mar; 42(2):90-3. PubMed ID: 16527909
    [Abstract] [Full Text] [Related]

  • 27. Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study.
    Boswood A, Gordon SG, Häggström J, Vanselow M, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Schummer C, Watson P.
    J Vet Intern Med; 2020 May; 34(3):1108-1118. PubMed ID: 32200574
    [Abstract] [Full Text] [Related]

  • 28. Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study.
    Apple SM, Menciotti G, Braz-Ruivo L, Crosara S, Häggström J, Borgarelli M.
    Aust Vet J; 2016 Sep; 94(9):324-8. PubMed ID: 27569835
    [Abstract] [Full Text] [Related]

  • 29. Tissue Doppler and strain imaging in dogs with myxomatous mitral valve disease in different stages of congestive heart failure.
    Tidholm A, Ljungvall I, Höglund K, Westling AB, Häggström J.
    J Vet Intern Med; 2009 Sep; 23(6):1197-207. PubMed ID: 19909428
    [Abstract] [Full Text] [Related]

  • 30. Investigation of pimobendan versus benazepril in canine myxomatous valvular disease.
    Boswood A, McEwan JD, French A, Little C, Swift S, Smith S, Patteson M.
    Vet Rec; 2003 Oct 04; 153(14):439-40. PubMed ID: 14582738
    [No Abstract] [Full Text] [Related]

  • 31. Use of pimobendan in 170 cats (2006-2010).
    Macgregor JM, Rush JE, Laste NJ, Malakoff RL, Cunningham SM, Aronow N, Hall DJ, Williams J, Price LL.
    J Vet Cardiol; 2011 Dec 04; 13(4):251-60. PubMed ID: 22030289
    [Abstract] [Full Text] [Related]

  • 32. Clinical findings and survival time in dogs with advanced heart failure.
    Beaumier A, Rush JE, Yang VK, Freeman LM.
    J Vet Intern Med; 2018 May 04; 32(3):944-950. PubMed ID: 29635788
    [Abstract] [Full Text] [Related]

  • 33. Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: a retrospective study of 141 cases.
    Pouchelon JL, Jamet N, Gouni V, Tissier R, Serres F, Carlos Sampedrano C, Castaignet M, Lefebvre HP, Chetboul V.
    J Vet Intern Med; 2008 May 04; 22(4):905-14. PubMed ID: 18482278
    [Abstract] [Full Text] [Related]

  • 34. Partial external mitral annuloplasty in dogs with myxomatous mitral valve degeneration and congestive heart failure: outcome in 9 cases.
    de Andrade JN, Christopher Orton E, Boon J, Nishimori CT, Olivaes C, Camacho AA.
    J Vet Cardiol; 2011 Sep 04; 13(3):197-201. PubMed ID: 21824833
    [Abstract] [Full Text] [Related]

  • 35. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation.
    Kvart C, Häggström J, Pedersen HD, Hansson K, Eriksson A, Järvinen AK, Tidholm A, Bsenko K, Ahlgren E, Ilves M, Ablad B, Falk T, Bjerkfås E, Gundler S, Lord P, Wegeland G, Adolfsson E, Corfitzen J.
    J Vet Intern Med; 2002 Sep 04; 16(1):80-8. PubMed ID: 11822810
    [Abstract] [Full Text] [Related]

  • 36. Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency.
    Atkins CE, Keene BW, Brown WA, Coats JR, Crawford MA, DeFrancesco TC, Edwards NJ, Fox PR, Lehmkuhl LB, Luethy MW, Meurs KM, Petrie JP, Pipers FS, Rosenthal SL, Sidley JA, Straus JH.
    J Am Vet Med Assoc; 2007 Oct 01; 231(7):1061-9. PubMed ID: 17916031
    [Abstract] [Full Text] [Related]

  • 37. Effect of oral administration of pimobendan in cats with heart failure.
    Gordon SG, Saunders AB, Roland RM, Winter RL, Drourr L, Achen SE, Hariu CD, Fries RC, Boggess MM, Miller MW.
    J Am Vet Med Assoc; 2012 Jul 01; 241(1):89-94. PubMed ID: 22720992
    [Abstract] [Full Text] [Related]

  • 38. Heart rate, heart rate variability, and arrhythmias in dogs with myxomatous mitral valve disease.
    Rasmussen CE, Falk T, Zois NE, Moesgaard SG, Häggström J, Pedersen HD, Ablad B, Nilsen HY, Olsen LH.
    J Vet Intern Med; 2012 Jul 01; 26(1):76-84. PubMed ID: 22151356
    [Abstract] [Full Text] [Related]

  • 39. An update on treatment and prognostic indicators in canine myxomatous mitral valve disease.
    Häggström J, Höglund K, Borgarelli M.
    J Small Anim Pract; 2009 Sep 01; 50 Suppl 1():25-33. PubMed ID: 19765217
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of pimobendan in dogs with cardiomegaly caused by preclinical mitral valve disease.
    Boswood A, Smith S, Patteson M.
    Vet Rec; 2011 Feb 26; 168(8):222. PubMed ID: 21493561
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.